SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is experiencing strong upward momentum following preliminary fourth-quarter revenue that significantly exceeded expectations, solidifying its role as a prominent defense drone manufacturer. The community is buzzing about the company's transition to a performance growth stock and eagerly awaits details on future contracts, particularly from the ongoing 'Drone Dominance Gauntlet' program. This positive sentiment is further amplified by broader market anticipation of increased defense spending and upcoming insights from the CEO's appearance at a major growth conference.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending with high short interest and a recent positive analyst rating, fueling significant short squeeze speculation ahead of its J.P. Morgan Healthcare Conference presentation. Community discussions are heavily focused on potential new partnerships, particularly for its Matrix-M adjuvant in oncology and other infectious diseases. Despite the company's scientific potential and recent de-risking updates, investors remain keenly attuned to management's ability to execute on these growth opportunities amidst ongoing debates about leadership.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobe is trending as a major point of contention, with recent analyst downgrades intensifying concerns about its market position against a backdrop of increasing AI-powered competition. The community is sharply divided, debating whether the creative software giant is a deeply undervalued opportunity or facing significant headwinds from rivals like Apple and evolving AI solutions.

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Travere Therapeutics Inc

Travere Therapeutics (TVTX) is trending after the FDA recently extended the review timeline for its supplemental New Drug Application for FILSPARI in FSGS to April 2026, classifying the company's additional responses as a Major Amendment. While the news initially prompted a significant stock decline, many in the community are debating whether this extension is a positive indicator, rather than an outright rejection, citing historical precedents of other biotech drugs that eventually gained approval after similar delays. Traders are actively discussing the resulting volatility and potential for a bounce, considering FILSPARI's promise as a first-in-class treatment for this rare kidney disorder.

BlackRock Institutional Trust Company N.A. - iShares Russell 2000 ETF

iShares Russell 2000 ETF

The iShares Russell 2000 ETF (IWM) is generating significant buzz, with many in the community celebrating its impressive breakout to new all-time highs as money rotates into small-cap stocks. This strong upward momentum is fueling discussions about whether small caps will continue to lead, particularly with upcoming economic data and the anticipated Supreme Court ruling on tariffs potentially influencing market sentiment.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd

SU Group Holdings Ltd (SUGP) is trending as traders eagerly eye its ultra-low share float and significant short interest, sparking intense speculation about a major short squeeze. The community is drawing strong comparisons to past high-volatility runners like SMX, with sentiment further fueled by high borrowing costs, its presence on the Reg SHO list, and upcoming earnings and contract news as potential catalysts.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

The iShares Silver Trust ($SLV) is a focal point of discussion amid extreme volatility and the CME Group's recent shift to percentage-based margin requirements for silver futures, intensifying market speculation. Bulls anticipate significantly higher prices, citing strong physical demand and trapped shorts, while bears warn of an imminent "rug pull" due to overbought conditions and the new margin rules. This creates a heated debate between those focused on underlying supply dynamics and concerns over paper market manipulation.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is experiencing notable volatility and a price dip, igniting strong community debate around its immediate future. Many investors are seizing the "buy the dip" opportunity, emphasizing the company's robust fundamentals, zero debt, and strategic positioning in agentic AI, despite others citing recent CEO share sales and broader software sector weakness as driving factors. This sharp divergence in sentiment underscores high expectations for either a continued pullback or a significant upward reversal.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is experiencing significant upward momentum driven by positive regulatory advancements for its seasonal flu and next-generation COVID-19 vaccine candidates, alongside promising results from a recent vaccine trial and new funding for a pivotal flu study. The community is actively discussing a potential short squeeze amidst high short interest, with many expressing renewed confidence in Moderna's diverse mRNA pipeline, particularly its oncology partnership.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. It focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan is trending after its Q4 earnings report, which, despite beating estimates, saw the stock react to concerns over a proposed credit card interest rate cap and a significant reserve build related to acquiring the Apple Card portfolio. Community discussion is split between those who view the cap as a substantial threat to bank profitability and others seeing the dip as a prime buying opportunity. Jamie Dimon's cautious economic outlook further fuels market debate around the financial sector's near-term direction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Taysha Gene Therapies, Inc. (TSHA) rallied 49% by Thursday morning after the U.S. Food and Drug Administration granted Breakthrough Therapy designation to its gene therapy TSHA-102 for the treatment of Rett syndrome.Rett syndrome is a rare genetic neurological and developmental disorder that affects the way the brain develops. The disorder, which primarily occurs in females, is characterized by loss of communication and hand function, slowing and/or regression of development, motor and respiratory impairment, seizures, intellectual disabilities, and shortened life expectancy.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-fda-breakthrough-therapy">According</a> to Taysha, there are currently no approved disease-modifying therapies that treat the genetic root cause of the disease, which affects between 15,000 and 20,000 patients in the U.S., the EU, and the U.K.The FDA on Thursday granted Taysha’s TSHA-102 Breakthrough Therapy designation. It is intended to expedite the development and regulatory review of an investigational therapy intended to treat a serious condition. The designation follows the agency’s review of available clinical data from the 12 patients treated in a part of its early-to mid-stage trials.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TSHA">TSHA stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume improved from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:573/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_02_at_11_39_41_AM_png_8ca9f60f70.webp" alt="TSHA's Sentiment Meter and Message Volume as of 11:39 a.m. ET on Oct. 02, 2025 | Source: Stocktwits" width="573" height="63"><figcaption>TSHA's Sentiment Meter and Message Volume as of 11:39 a.m. ET on Oct. 02, 2025 | Source: Stocktwits</figcaption></figure>Taysha also said on Thursday that it has finalized alignment with the FDA on the protocol for the trial intended to support its application for approval of TSHA-102. The company is now on track to begin patient enrollment in the trial in the fourth quarter of 2025. In the trial, a single intrathecal administration of high-dose TSHA-102 will be evaluated in 15 females between the ages of six and below 22 years with Rett syndrome.Following the news, Needham analyst Gil Blum raised the firm's price target on Taysha Gene Therapies to $10 from $8 while keeping a ‘Buy’ rating on the shares. Needham views the developments as "derisking" for TSHA-102, putting the program well ahead of Neurogene’s gene therapy NGN-401, which is also being evaluated for Rett syndrome.TSHA stock has risen 174% this year and by about 131% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-reports-7-percent-rise-in-q3-deliveries/chCrXlDR3Ow">Tesla’s Q3 Deliveries Hit Quarterly Record, Rise 7% To Exceed Analyst Estimates</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Taysha Gene Therapies Stock Soars After FDA Grants Breakthrough Therapy Designation To Gene Therapy

Taysha also announced that it has finalized alignment with the FDA on the protocol for the trial intended to support its application for approval of TSHA-102.

Equity

Taysha also announced that it has finalized alignment with the FDA on the protocol for the trial intended to support its application for approval of TSHA-102.


Texas Capital Funds Trust - Texas Capital Texas Small Cap Equity Index ETF

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

TXSS
Texas Capital Funds Trust - Texas Capital Texas Small Cap Equity Index ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest TXSS News

TXSSTexas Capital Funds Trust - Texas Capital Texas Small Cap Equity Index ETF